Linc AB
SSTO:LINC68.40
SEK
+0.60
(+0.88%)
ISIN
SE0015949433
Return %
Stock
S&P 500
1Y
-4.07
14.20
3Y
26.67
81.12
5Y
-22.55
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Snickar Karl Johan Tobieson
- Full Time Employees
- 2
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- Vasagatan 28 Stockholm AB Sweden 111 20
- IPO Date
- May 28, 2021
- Website
- linc.se
- Similar Companies
- Business
- Linc AB operates as an investment company, specializing in both private equity and venture capital, with a dedicated focus on the Nordic life science industry. The firm directs its capital toward product-oriented businesses, primarily within the pharmaceutical and medical technology sectors. Linc strategically invests across various development stages, typically engaging in pharmaceutical endeavors during earlier phases, while entering medical technology ventures at more mature points. The company, which successfully completed its initial public offering on Nasdaq Stockholm in May 2021, prefers to secure long-term share ownership in these companies, encompassing both publicly traded and privately held entities. Investments typically range from SEK 25 million to SEK 250 million, often starting with a smaller initial commitment that is then augmented by subsequent, more substantial follow-on investments. Linc acts as an active, long-term owner, providing not just financial backing but also valuable expertise, extensive industry networks, and strategic support to its portfolio companies. The company is headquartered in Stockholm, Sweden.